Company intelligence / Profile preview

Asceneuron SA

Ownership: Private
Employees: ~20
Development stage: Phase 2

Overview

Asceneuron has completed five Phase I clinical trials with its lead OGA inhibitor ASN51, demonstrating full central nervous system uptake and high target engagement. ASN51 will enter its first Phase II trial for Alzheimer’s disease in the second half of 2024. Another OGA inhibitor, ASN90, was licensed to Ferrer Pharmaceuticals for progressive supranuclear palsy. The company also has preclinical programs targeting Parkinson’s and ALS[2][6][7].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

ASN51

3 more assets in the full pipeline.

Request access →

Partnerships

Ferrer PharmaceuticalsCritical Path Institute – CPAD Consortium

Beyond the preview

Go deeper on Asceneuron SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asceneuron SA.

Explore the full profile